What Future Pak does

Future Pak, LLC is a privately owned pharmaceutical contract packaging and manufacturing organization (CDMO) headquartered in Wixom, Michigan, founded in 1976-1977 and operating continuously for nearly 50 years. The company operates three FDA-registered, GDUFA-compliant, EU-certified facilities totaling more than 60,000 square feet with climate-controlled warehousing. Its core offering spans five primary packaging formats — blister packs (including deep draw and cold form tooling on two Klockner CP3 thermoforming lines), bottles (with inline check weighing and vision inspection), stick packs, pouches (horizontal and vertical form-fill-seal), and cartoning (with off-line serialization) — qualified for OTC, prescription (Rx), and supplement products. Future Pak also manufactures proprietary activated charcoal capsules marketed for toxin-binding applications including detox, mold/metal exposure, and emergency response. The company reaches customers primarily through direct B2B sales, website inquiries, and phone contact, with project-based contract packaging as its baseline revenue model.

In January 2026, Future Pak executed a strategic expansion beyond pure contract services by acquiring exclusive U.S. marketing rights to two FDA-approved crofelemer-based drugs — Mytesi and Canalevia-CA1 — from Jaguar Health's Napo Pharmaceuticals subsidiary for an $18-19 million upfront payment plus up to $20 million in milestones, with an additional $3 million paid in March 2026 to extend commercialization rights beyond the original five-year period. Future Pak now commercializes these drugs while Napo continues manufacturing, marking a pivot toward branded pharmaceutical distribution. The company has additionally made three acquisition attempts for HIV-focused biopharma TheraTechnologies, culminating in a $255 million offer in April 2025 ($205 million cash at closing plus up to $50 million in contingent value rights). The company maintains an affiliate relationship with Woodward Specialty LLC, which participates in inventory and commercial structuring for the Jaguar Health deal. Revenue model combines project-based contract packaging fees with licensing and commercialization economics from the Jaguar partnership; pricing is quote-based and not publicly disclosed.

Name

Future Pak

Legal name

Future Pak, LLC

Website

https://futurepak.com

Company type

Private

Founded year

1976

Operating status

Operating

Headcount range

51–100 employees

Short description

Future Pak is a privately owned Michigan-based pharmaceutical CDMO offering blister packs, bottles, stick packs, pouches, and cartoning services, plus activated charcoal capsule manufacturing, serving pharmaceutical, OTC, and supplement companies with FDA-compliant packaging.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Packaging & Manufacturing

NAICS

Packaging and Labeling Services (561910), Metal Can, Box, and Other Metal Container (Light Gauge) Manufacturing (33243), Other Metal Container Manufacturing (332439)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Professional & Commercial Equipment & Supplies (5040), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical packaging services
• Contract manufacturing organization
• Blister packaging
• Activated charcoal capsules
• FDA compliant packaging

Headquarters

HQ city

Wixom

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Packaging Services: Provides contract packaging services for pharmaceutical companies including blister packs, bottles, stick packs, pouching, and cartoning. Revenue generated through per-project manufacturing agreements with pharmaceutical, OTC, and supplement companies requiring FDA-compliant packaging solutions.
2. Licensing/Commercialization Rights: Acquired exclusive U.S. marketing rights for Mytesi and Canalevia-CA1 drugs from Jaguar Health through a licensing agreement. Received $18-19 million upfront plus potential milestone payments up to $20 million. Future Pak markets these FDA-approved drugs while Jaguar continues manufacturing.
3. Acquisition/Buyout Offers: Made a $255 million acquisition offer for TheraTechnologies ($205 million cash at closing plus up to $50 million in contingent value rights), representing attempts to expand through M&A activity in the CDMO/pharmaceutical space.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Future Pak is a privately owned contract development and manufacturing organization (CDMO) that provides specialized pharmaceutical packaging services, including blister packs, bottles, stick packs, pouching, and cartoning, for prescription (Rx), OTC, and dietary supplement products. The company also manufactures activated charcoal capsules used for toxin binding in daily and emergency applications. Operations are conducted from three FDA-registered, GDUFA-compliant facilities totaling over 60,000 sq. ft. in Wixom, Michigan.

Product overview

Future Pak is a pharmaceutical packaging solutions provider offering a suite of packaging services including blister packs, bottles, stick packs, pouching, and cartoning, complemented by activated charcoal capsule manufacturing. The company operates three state-of-the-art facilities spanning over 60,000 sq. ft. in Wixom, MI, providing flexible small or large run capabilities for pharmaceutical, OTC, prescription, and dietary supplement products. The packaging services work together as an integrated offering where clients can access multiple packaging formats through a single provider, with serialization and compliance capabilities built into the manufacturing processes.

Differentiator

Problem solved

Functional benefit

Products and services

• Blister Pack Packaging Contract blister packaging service offering a wide selection of configurations including deep draw and cold form tooling, using two Klockner CP3 thermoforming lines with an automated inline carton system, leaflet inserter, and ACG serialization. Designed for pharmaceutical companies requiring FDA-compliant unit-dose packaging.
• Bottle Packaging Contract bottle packaging service for OTC, prescription (Rx), and supplement products. Includes a fully equipped bottle suite with inline check weighing, vision inspection, full-disclosure wrap-around labels, security neck bands, shrink sleeves, and ACG serialization for bottles. Supports oral solids, granules, and powders.
• Stick Pack Packaging Measured-unit dose stick pack packaging service for powders and granules. Provides convenient, easy-to-carry dosage forms with individual cup adjustments for accurate weights and multiple stick pack dimensions for OTC and dietary supplement products.
• Pouching Form fill and seal pouching service offering both horizontal and vertical lines configured for tablets, capsules, powders, and granules. Two suites accommodate tabs, powders, and granules, with Bartelt-type lines configured for pre-printed materials and multiple vertical lines for tablets and capsules.
• Cartoning Automated horizontal cartoning service that builds, closes, and folds sealed cartons with glue closure and weigh-cell verification. Provides off-line serialization solutions for offline packaging operations.
• Activated Charcoal Capsules Manufactured activated charcoal capsules that bind with toxins and help eliminate them from the body. Intended for daily use or emergency situations including mold or metal exposure, detox, or alcohol poisoning.

Quantifiable outcome

• Pristine compliance record with zero warning letters in nearly 50 years of operation

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• TheraTechnologiesminorStrategic or Co-development Partner · 14 April 2025Future Pak made a $255 million acquisition offer for the HIV-focused biopharma ($205 million cash at closing plus up to $50 million in CVRs); this was the CDMO's third attempt at a buyout following rejected proposals in August 2024 and January 2025; TheraTechnologies was already under exclusivity with another potential buyer

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Jones Packaging: Long-established contract pharmaceutical packaging provider with blister, bottle, vial and serialization capabilities — closely comparable to Future Pak in solid-dose contract packaging, compliance track record and mid-market pharma client base.
• PCI Pharma Services: Global pharmaceutical contract services company offering integrated drug development, manufacturing and commercial packaging — directly comparable to Future Pak across blister packaging, bottling, serialization and clinical/commercial packaging services for solid oral dose formats.
• CoreRx: Contract pharmaceutical development and manufacturing company providing formulation, clinical manufacturing and commercial packaging — overlapping directly with Future Pak's CDMO solid-dose packaging capabilities.
• Adare Pharmaceuticals (Adare Pharma Solutions): CDMO offering formulation, finished-dose manufacturing and packaging services for solid oral dosage forms, similar in scope and customer base to Future Pak's packaging and pharmaceutical manufacturing services.
• Mikart: U.S. contract development and manufacturing organization focused on solid oral dose products, including packaging services comparable to Future Pak's blister, bottle and small-run CDMO offerings.
• Sharp Packaging Solutions (Ashfield): Specialist pharmaceutical contract packaging division offering blister, bottle, vial, syringe and serialization solutions — directly comparable to Future Pak in solid-dose commercial packaging, serialization and FDA-compliant packaging operations.

Broad incumbents

• Catalent: One of the largest global CDMOs spanning softgel, oral solid, biologics and sterile fill-finish with extensive packaging capabilities; while Far broader and much larger than Future Pak, Catalent competes for the same pharmaceutical packaging work and represents the scale benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/future_pak_ltd

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Pak